No Data
No Data
Form 144 | Beam Therapeutics(BEAM.US) Officer Proposes to Sell 4.27 Million in Common Stocks
SEC FILLINGS DISCLOSED/ Oct 7, $Beam Therapeutics(BEAM.US)$ Officer Burrell Terry-Ann intends to sell 185.57K shares of its common stock on Oct 7, with a total market value of approximately $4.27
Here's Why We're Not At All Concerned With Beam Therapeutics' (NASDAQ:BEAM) Cash Burn Situation
Beam Therapeutics Price Target Maintained With a $27.00/Share by RBC Capital
RBC Capital Maintains Beam Therapeutics(BEAM.US) With Hold Rating, Maintains Target Price $27
RBC Capital analyst Luca Issi maintains $Beam Therapeutics(BEAM.US)$ with a hold rating, and maintains the target price at $27.According to TipRanks data, the analyst has a success rate of 22.6% and
RBC Capital Sticks to Its Hold Rating for Beam Therapeutics (BEAM)
Jones Trading Initiates Coverage On Beam Therapeutics With Hold Rating